secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001193125-26-091482
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences Q4 revenue $20.4M (+7% YoY); guides 2026 revenue $82-88M
-----------------------------------------------------------------------

- Q4 2025 revenue $20.4M (+7% YoY); Interventional Glaucoma $19.7M (+5% YoY); Dry Eye $0.7M vs $0.3M.
- Q4 net loss $4.2M ($0.08 loss per share) vs $11.8M loss in Q4 2024; full-year net loss $38.4M vs $51.5M.
- Cash $92M at Dec 31, 2025; Q4 cash used only $0.4M; full-year cash used $28.4M.
- FY 2026 guidance: revenue $82-88M (+6-14% YoY); Glaucoma $77-81M; Dry Eye $5-7M.
- Operating expenses down 25% Q4 and 13% full-year; adjusted op ex guidance $93-96M for 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000119312526091482/0001193125-26-091482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000119312526091482/sght-20260304.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-091482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer